William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.
|Videos|October 7, 2017
Greater Risk of Death in Cancer Patients Who Choose Alternative Therapies
Author(s)Skyler Johnson, MD
This video highlights a recent study that looked at the survival impact of cancer patients who chose alternative medicine instead of conventional cancer treatments.
Advertisement
In this video, Skyler Johnson, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses a study that looked at the survival impact of cancer patients who chose alternative medicine instead of conventional cancer treatments.
The study was recently
Johnson presented the results at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego (
Advertisement
Related to this article
Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.
In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.
Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.
Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.
The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
5